WO2014011876A2 - Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia - Google Patents

Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia Download PDF

Info

Publication number
WO2014011876A2
WO2014011876A2 PCT/US2013/050071 US2013050071W WO2014011876A2 WO 2014011876 A2 WO2014011876 A2 WO 2014011876A2 US 2013050071 W US2013050071 W US 2013050071W WO 2014011876 A2 WO2014011876 A2 WO 2014011876A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
calcium
ppm
magnesium
range
Prior art date
Application number
PCT/US2013/050071
Other languages
English (en)
French (fr)
Other versions
WO2014011876A3 (en
Inventor
Donald Jeffrey Keyser
Alvaro F. GUILLEM
Original Assignee
ZS Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP13817161.6A priority Critical patent/EP2872148A4/en
Priority to KR1020157003699A priority patent/KR20150036555A/ko
Priority to IN201KON2015 priority patent/IN2015KN00201A/en
Priority to HK16103833.7A priority patent/HK1215861A1/zh
Priority to HK15109434.8A priority patent/HK1209029A1/xx
Priority to MX2015000381A priority patent/MX2015000381A/es
Priority to BR112015000636A priority patent/BR112015000636A2/pt
Priority to AU2013290141A priority patent/AU2013290141A1/en
Application filed by ZS Pharma, Inc. filed Critical ZS Pharma, Inc.
Priority to CN201380047054.7A priority patent/CN104968336A/zh
Priority to JP2015521806A priority patent/JP2015529640A/ja
Priority to CA2878832A priority patent/CA2878832A1/en
Publication of WO2014011876A2 publication Critical patent/WO2014011876A2/en
Priority to IL236655A priority patent/IL236655A0/en
Priority to PH12015500071A priority patent/PH12015500071A1/en
Publication of WO2014011876A3 publication Critical patent/WO2014011876A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0006—Controlling or regulating processes
    • B01J19/0013—Controlling the temperature of the process
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0053—Details of the reactor
    • B01J19/006—Baffles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0053—Details of the reactor
    • B01J19/0066—Stirrers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/18—Stationary reactors having moving elements inside
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/02—Processes using inorganic exchangers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/14—Base exchange silicates, e.g. zeolites
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/025—Silicon compounds without C-silicon linkages
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00049—Controlling or regulating processes
    • B01J2219/00051—Controlling the temperature
    • B01J2219/00054—Controlling or regulating the heat exchange system
    • B01J2219/00056—Controlling or regulating the heat exchange system involving measured parameters
    • B01J2219/00058—Temperature measurement
    • B01J2219/00063—Temperature measurement of the reactants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00049—Controlling or regulating processes
    • B01J2219/00051—Controlling the temperature
    • B01J2219/00074—Controlling the temperature by indirect heating or cooling employing heat exchange fluids
    • B01J2219/00087—Controlling the temperature by indirect heating or cooling employing heat exchange fluids with heat exchange elements outside the reactor
    • B01J2219/00094—Jackets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00761—Details of the reactor
    • B01J2219/00763—Baffles
    • B01J2219/00765—Baffles attached to the reactor wall
    • B01J2219/00768—Baffles attached to the reactor wall vertical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to novel microporous zirconium silicate ("ZS") compositions that are formulated to remove toxins, e.g., potassium ions or ammonium ions, from the gastrointestinal tract at an elevated rate while avoiding the removal of calcium.
  • ZS microporous zirconium silicate
  • the preferred compositions of the present invention also avoid certain undesirable side effects including potential entry of particles into the bloodstream and potential increase in pH of urine in patients. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
  • microporous ZS compositions having enhanced purity and potassium exchange capacity (KEC), and methods for making such microporous ZS compositions.
  • KEC potassium exchange capacity
  • the present invention relates to the use of microporous ZS compositions to remove calcium from hypercalcemic patients as well as toxins such as potassium or ammonium ions.
  • Acute hyperkalemia is a serious life threatening condition resulting from elevated serum potassium levels.
  • Potassium is a ubiquitous ion, involved in numerous processes in the human body. It is the most abundant intracellular cation and is critically important for numerous physiological processes, including maintenance of cellular membrane potential, homeostasis of cell volume, and transmission of action potentials. Its main dietary sources are vegetables (tomatoes and potatoes), fruit (oranges, bananas) and meat.
  • the normal potassium levels in plasma are between 3.5-5.0 mmol/1 with the kidney being the main regulator of potassium levels.
  • the renal elimination of potassium is passive (through the glomeruli) with active reabsorption in the proximal tubule and the ascending limb of the loop of Henle. There is active excretion of potassium in the distal tubules and the collecting duct, both of these processes are controlled by aldosterone.
  • Hyperkalemia may develop when there is excessive production of serum potassium (oral intake, tissue breakdown). Ineffective elimination, which is the most common cause of hyperkalemia, can be hormonal (as in aldosterone deficiency), pharmacologic (treatment with ACE-inhibitors or angiotensin-receptor blockers) or, more commonly, due to reduced kidney function or advanced cardiac failure. The most common cause of hyperkalemia is renal insufficiency, and there is a close correlation between degree of kidney failure and serum potassium (S-K) levels. In addition, a number of different commonly used drugs cause hyperkalemia, such as ACE-inhibitors, angiotensin receptor blockers, potassium-sparing diuretics (e.g.
  • beta-receptor blocking agents digoxin or succinylcholine are other well-known causes of hyperkalemia.
  • advanced degrees of congestive heart disease, massive injuries, burns or intravascular hemolysis cause hyperkalemia, as can metabolic acidosis, most often as part of diabetic ketoacidosis.
  • Symptoms of hyperkalemia are somewhat non-specific and generally include malaise, palpitations and muscle weakness or signs of cardiac arrhythmias, such as palpitations, brady- tachycardia or dizziness/fainting. Often, however, the hyperkalemia is detected during routine screening blood tests for a medical disorder or after severe complications have developed, such as cardiac arrhythmias or sudden death. Diagnosis is obviously established by S-K
  • Treatment depends on the S-K levels. In milder cases (S-K between 5-6.5 mmol/1), acute treatment with a potassium binding resin (Kayexalate®), combined with dietary advice (low potassium diet) and possibly modification of drug treatment (if treated with drugs causing hyperkalemia) is the standard of care; if S-K is above 6.5 mmol/1 or if arrhythmias are present, emergency lowering of potassium and close monitoring in a hospital setting is mandated.
  • the following treatments are typically used: • Kayexalate , a resin that binds potassium in the intestine and hence increases fecal excretion, thereby reducing S-K levels.
  • Kayexalate ® has been shown to cause intestinal obstruction and potential rupture. Further, diarrhea needs to be simultaneously induced with treatment. These factors have reduced the palatability of treatment with Kayexalate ® .
  • Insulin IV (+ glucose to prevent hypoglycemia), which shifts potassium into the cells and away from the blood.
  • Calcium supplementation Calcium does not lower S-K, but it decreases myocardial excitability and hence stabilizes the myocardium, reducing the risk for cardiac arrhythmias.
  • Bicarbonate The bicarbonate ion will stimulate an exchange of K+ for Na+, thus leading to stimulation of the sodium-potassium ATPase.
  • Kayexalate ® cannot be administered on a chronic basis, and even in the acute setting, with the accompanying need to induce diarrhea, combined with only marginal efficacy and a foul smell and taste, reduces its usefulness.
  • known ZS compositions may exhibit undesirable effects when utilized in vivo for the removal of potassium in the treatment of hyperkalemia.
  • the administration of ZS molecular sieve compositions has been associated with an incidence of mixed leukocyte inflammation, minimal acute urinary bladder inflammation and the observation of unidentified crystals in the renal pelvis and urine in animal studies, as well as an increase in urine pH.
  • known ZS compositions have had issues with crystalline impurities and undesirably low cation exchange capacity.
  • the '080 application discloses novel ZS molecular sieves to address the problem associated with existing hyperkalemia treatments, and novel methods of treatment for hyperkalemia utilizing these novel compositions.
  • U.S. Provisional Patent Application No. 61/658117 the ⁇ 17 application
  • the present inventors disclosed novel ZS products and methods of manufacturing.
  • the present inventors have now discovered that treatment of hyperkalemia with the ZS compositions disclosed in the ⁇ 80 and ⁇ 17 applications is accompanied by a withdrawal of significant amounts of calcium from the patient's body.
  • ZS and zirconium germanate molecular sieves have a microporous structure composed of Zr0 3 octahedral units and at least one Si0 2 tetrahedral units and Ge0 2 tetrahedral units. These molecular sieves have the empirical formula:
  • A is an exchangeable cation selected from potassium ion, sodium ion, rubidium ion, cesium ion, calcium ion, magnesium ion, hydronium ion or mixtures thereof
  • M is at least one framework metal selected from the group consisting of hafnium (4+), tin (4+), niobium (5+), titanium (4+), cerium (4+), germanium (4+), praseodymium (4+), and terbium (4+)
  • p has a value from about 1 to about 20
  • "x” has a value from 0 to less than 1
  • n has a value from about 0 to about 12
  • y has a value from 0 to about 12
  • m has a value from about 3 to about 36 and 1 ⁇ n + y ⁇ 12.
  • the germanium can substitute for the silicon, zirconium or combinations thereof. Since the compositions are essentially insoluble in bodily fluids (at neutral or basic pH), they can be orally ingested in order to remove toxins in the gastrointestinal system.
  • the compositions of the present invention comprise an elevated level of calcium that allows the compositions to treat hyperkalemia without withdrawing calcium from the patient's body or without withdrawing undesirable amounts of calcium from the patient's body.
  • the ZS compositions comprise calcium levels ranging from 1 to 100 ppm, preferably from 1 to 30 ppm, and more preferably between 5 and 25 ppm.
  • the compositions of the present invention preferably have a calcium content that is sufficient to avoid absorption of significant amounts of calcium from the patient's body while maintaining high potassium exchange capacity.
  • any divalent cation may be absorbed onto the ZS composition to lessen the interaction and absorption of calcium with the composition.
  • the calcium may be substituted by any divalent cation.
  • the divalent cation may be selected from any of the elements found in group 2 of the periodic table or alkaline earth metals.
  • the divalent cation is preferably selected from calcium or magnesium. The divalent cation will be present in an amount effective to lessen the withdrawal of the calcium from a patient suffering from hyperkalemia.
  • a single type of divalent cation or a mixture of various types of divalent cations may be absorbed onto the ZS composition.
  • the ZS composition may comprise elevated levels of magnesium.
  • the ZS compositions comprise magnesium in levels ranging from 1 to 100 ppm, preferably from 1 to 30 ppm, and more preferably from 5 to 25 ppm.
  • the ZS compositions may comprise a mixture of both calcium and magnesium, where the ratio of calcium to magnesium ranges from 1 : 10 to 10: 1, preferably form 1 :5 to 5: 1, more preferably from 1 :2 to 2: 1.
  • the ratio of calcium to magnesium may be adjusted to any level to optimize the withdrawal of calcium from a hyperkalemic patient while at the same time having an optimal potassium exchange rate.
  • the composition exhibits median particle size of greater than 3 microns and less than 7% of the particles in the composition have a diameter less than 3 microns.
  • less than 5% of the particles in the composition have a diameter less than 3 microns, more preferably less than 4% of the particles in the composition have a diameter less than 3 microns, more preferably less than 3% of the particles in the composition have a diameter of less than 3 microns, more preferably less than 2% of the particles in the composition have a diameter of less than 3 microns, more preferably less than 1% of the particles in the composition have a diameter of less than 3 microns, more preferably less than 0.5% of the particles in the
  • compositions have a diameter of less than 3 microns. Most preferably, none of the particles or only trace amounts have a diameter of less than 3 microns.
  • the median and average particle size is preferably greater than 3 microns and particles reaching a sizes on the order of 1,000 microns are possible for certain applications.
  • the median particle size ranges from 5 to 1000 microns, more preferably 10 to 600 microns, more preferably from 15 to 200 microns, and most preferably from 20 to 100 microns.
  • the composition exhibiting the median particle size and fraction of particles in the composition having a diameter less than 3 micron described above also exhibits a sodium content of below 12% by weight.
  • the sodium contents is below 9% by weight, more preferably the sodium content is below 6% by weight, more preferably the sodium content is below 3% by weight, more preferably the sodium content is in a range of between 0.05 to 3% by weight, and most preferably 0.01% or less by weight or as low as possible.
  • the invention involves a pharmaceutical product comprising the composition in capsule, powdered, or tablet form.
  • the pharmaceutical product is packaged in a kit in individual unit dosages sufficient to maintain a lowered serum potassium level.
  • the dosage may range from approximately 1-60 grams per day or any whole number or integer interval therein.
  • Such dosages can be individual capsules, tablets, or packaged powdered form of 1.25-20 grams of the ZS, preferably 2.5-15 grams of ZS, more preferably 5-10 grams of ZS.
  • the ZS may be a single unit dose of approximately 1.25-45 gram capsule, tablet or powdered package.
  • the product may be consumed once a day, three times daily, every other day, or weekly.
  • a molecular sieve which has an elevated cation exchange capacity, particularly potassium exchange capacity.
  • the elevated cation exchange capacity is achieved by a specialized process and reactor configuration that lifts and more thoroughly suspends crystals throughout the reaction.
  • the ZS-9 crystals had a potassium exchange capacity of greater than 2.5 meq/g, more preferably greater than 3.5 meq/g, more preferably greater than 4.0 meq/g, more preferably between 4.3 and 4.8 meq/g, even more preferably between 4.4 and 4.7 meq/g, and most preferably approximately 4.5 meq/g.
  • ZS-9 crystals having a potassium exchange capacity in the range of 3.7-3.9 were produced in accordance with Example 13 below.
  • the improved ZS-9 crystal compositions (i.e., compositions where the predominant crystalline form is ZS-9) had a potassium exchange capacity of greater than 2.5 meq/g, more preferably between 2.7 and 3.7 meq/g, more preferably between 3.05 and 3.35 meq/g.
  • ZS-9 crystals with a potassium exchange capacity of 3.1 meq/g have been manufactured on a commercial scale and have achieved desirable clinical outcomes. It is expected that ZS-9 crystals with a potassium exchange capacity of 3.2 meq/g will also achieve desirable clinical outcomes and offer improved dosing forms.
  • the targets of 3.1 and 3.2 meq/g may be achieved with a tolerance of ⁇ 15%, more preferably ⁇ 10%, and most preferably ⁇ 5%.
  • ZS-9 Higher capacity forms of ZS-9 are desirable although are more difficult to produce on a commercial scale. Such higher capacity forms of ZS-9 have elevated exchange capacities of greater than 3.5 meq/g, more preferably greater than 4.0 meq/g, more preferably between 4.3 and 4.8 meq/g, even more preferably between 4.4 and 4.7 meq/g, and most preferably approximately 4.5 meq/g. ZS-9 crystals having a potassium exchange capacity in the range of between 3.7 and 3.9 meq/g.
  • compositions of the present invention may be used in the treatment of kidney disease (e.g., chronic or acute) or symptoms of kidney diseases, such as hyperkalemia (e.g., chronic or acute) comprising administering the composition to a patient in need thereof.
  • the administered dose may vary, depending on whether the treatment is for chronic or acute hyperkalemia.
  • the dose for treating acute hyperkalemia is higher than that for the treatment of chronic kidney disease
  • the dose preferably ranges from approximately 0.7 to 1,500 mg/Kg/day, more preferably from approximately 500 to 1,000 mg/Kg/day, and most preferably approximately 700 mg/Kg/day.
  • a typical daily dose for treatment of acute hyperkalemia, depending on the potassium exchange capacity, in a human patient will range from approximately 50 mg to 60 g per day, more preferably from approximately 1 mg to 30 g per day, more preferably 3 to 9 g per day, and most preferably approximately 3 g per day.
  • the dose preferably ranges from 0.25 to 100 mg/Kg/day, more preferably from 10 to 70 mg/Kg/day, and most preferably approximately 50 mg/Kg/day.
  • a typical daily dose for treatment of chronic hyperkalemia in a human patient will range from approximately 0.020 to 10 g per day, more preferably from 0.1 to 1 g per day, and most preferably approximately 0.5 g per day.
  • the dosages will typically be lower due to the increased effectiveness of the compositions for lowering potassium levels in a patient.
  • the dose preferably ranges from approximately 0.7 to 800 mg/Kg/day, more preferably from approximately 280 to 500 mg/Kg/day, and most preferably approximately 390 mg/Kg/day.
  • a typical daily dose for treatment of acute hyperkalemia, depending on the potassium exchange capacity, in a human patient will range from approximately 50 mg to 33 g per day, more preferably from approximately 1 mg to 30 g per day, more preferably 3 to 9 g per day, and most preferably approximately 3 g per day.
  • the dose preferably ranges from 0.25 to 55 mg/Kg/day, more preferably from 5 to 40 mg/Kg/day, and most preferably approximately 30 mg/Kg/day.
  • a typical daily dose for treatment of chronic hyperkalemia in a human patient will range from approximately 0.020 to 5 g per day, more preferably from 0.05 to 0.7 g per day, and most preferably approximately 0.5 g per day.
  • compositions of the invention may be prepared by subjecting a ZS composition as described above to screening or a combination of screening and ion exchange processes as further described herein. Further, the compositions may be prepared using the processes disclosed in the ⁇ 80 application discussed above.
  • the present invention includes the use of pre-existing microporous ZS compositions such as those disclosed in the '080 and ⁇ 17 applications in the treatment hyperkalemic in hypercalcemic patients. The present inventors have found that ZS compositions lacking added calcium can serve to withdraw excess calcium from patients which makes these compositions useful in the treatment of hyperkalemia in hypercalcemic patents as well as for the treatment of hypercalcemia.
  • Fig. 1 is a polyhedral drawing showing the structure of microporous ZS
  • Fig. 2 shows particle size distribution of ZS-9 lot 5332-04310-A in accordance with Example 8.
  • Fig. 3 shows particle size distribution of ZS-9 lot 5332-15410-A in accordance with Example 8.
  • Fig. 4 shows particle size distribution of ZS-9 preclinical lot in accordance with Example
  • Fig. 5 shows particle size distribution of lot 5332-0431 OA w/o screening in accordance with Example 9.
  • Fig. 6 shows particle size distribution of lot 5332-0431 OA 635 mesh in accordance with Example 9.
  • Fig. 7 shows particle size distribution of lot 5332-0431 OA 450 mesh in accordance with Example 9.
  • Fig. 8 shows particle size distribution of lot 5332-0431 OA 325 mesh in accordance with Example 9.
  • Fig. 9 shows particle size distribution of lot 5332-0431 OA 230 mesh in accordance with
  • Fig. 10 XRD plot for ZS-9 prepared in accordance with Example 12.
  • Fig. 11 FTIR plot for ZS-9 prepared in accordance with Example 12.
  • Fig. 12 XRD plot for ZS-9 prepared in accordance with Example 13.
  • Fig. 13 FTIR plot for ZS-9 prepared in accordance with Example 13.
  • Fig. 15 Example of the Assay Standard Solution Chromatogram.
  • Fig. 16 Exemplary Sample Chromatogram.
  • Fig. 17 Reaction vessel with standard agitator arrangement.
  • Fig. 18 Reaction vessel with baffles for production of enhanced ZS-9
  • Fig. 19 Detail of baffle design for 200-L reaction vessel for production of enhanced ZS-9
  • ZS has a microporous framework structure composed of Zr0 2 octahedral units and Si0 2 tetrahedral units.
  • Figure 1 is a polyhedral drawing showing the structure of
  • microporous ZS Naz19ZrSi3.01O9.11 . ⁇ 2.71FLO (MW 420.71)
  • the dark polygons depict the octahedral zirconium oxide units while the light polygons depict the tetrahedral silicon dioxide units. Cations are not depicted in Fig. 1.
  • the microporous exchanger of the invention has a large capacity and strong affinity, i.e., selectivity, for potassium or ammonium.
  • Eleven types of ZS are available, ZS-1 through ZS-11, each having various affinities to ions have been developed. See e.g., U.S. Patent No. 5,891,417.
  • ZS-9 is a particularly effective ZS absorber for absorbing potassium and ammonium. These ZSs have the empirical formula:
  • A is an exchangeable cation selected from potassium ion, sodium ion, rubidium ion, cesium ion, calcium ion, magnesium ion, hydronium ion or mixtures thereof
  • M is at least one framework metal selected from the group consisting of hafnium (4+), tin (4+), niobium (5+), titanium (4+), cerium (4+), germanium (4+), praseodymium (4+), and terbium (4+)
  • p has a value from about 1 to about 20
  • "x” has a value from 0 to less than 1
  • n has a value from about 0 to about 12
  • y has a value from 0 to about 12
  • m has a value from about 3 to about 36 and 1 ⁇ n + y ⁇ 12.
  • the germanium can substitute for the silicon, zirconium or combinations thereof. It is preferred that x and y are zero or both approaching zero, as germanium and other metals are often present in trace quantities. Since the compositions are essentially insoluble in bodily fluids (at neutral or basic pH), they can be orally ingested in order to remove toxins in the
  • ZS-8 has an increased solubility as compared to other forms of ZS (i.e., ZS-l-ZS-7, and ZSi-9-ZS-l 1).
  • ZS-l-ZS-7 forms of ZS
  • ZSi-9-ZS-l 1 soluble forms of ZS including ZS-8 are undesirable since soluble forms of ZS may contribute to elevated levels of zirconium and/or silicates in the urine.
  • Amorphous forms of ZS may also be substantially soluble. Therefore, it is desirable to reduce the proportion of amorphous material to the extent practicable.
  • the zirconium metallates are prepared by a hydrothermal crystallization of a reaction mixture prepared by combining a reactive source of zirconium, silicon and/or germanium, optionally one or more M metal, at least one alkali metal and water.
  • the alkali metal acts as a templating agent. Any zirconium compound, which can be hydrolyzed to zirconium oxide or zirconium hydroxide, can be used.
  • these compounds include zirconium alkoxide, e.g., zirconium n-propoxide, zirconium hydroxide, zirconium acetate, zirconium oxychloride, zirconium chloride, zirconium phosphate and zirconium oxynitrate.
  • the sources of silica include colloidal silica, fumed silica and sodium silicate.
  • the sources of germanium include germanium oxide, germanium alkoxides and germanium tetrachloride.
  • Alkali sources include potassium hydroxide, sodium hydroxide, rubidium hydroxide, cesium hydroxide, sodium carbonate, potassium carbonate, rubidium carbonate, cesium carbonate, sodium halide, potassium halide, rubidium halide, cesium halide, sodium ethylenediamine tetraacetic acid (EDTA), potassium EDTA, rubidium EDTA, and cesium EDTA.
  • the M metals sources include the M metal oxides, alkoxides, halide salts, acetate salts, nitrate salts and sulfate salts.
  • M metal sources include, but are not limited to titanium alkoxides, titanium tetrachloride, titanium trichloride, titanium dioxide, tin tetrachloride, tin isopropoxide, niobium isopropoxide, hydrous niobium oxide, hafnium isopropoxide, hafnium chloride, hafnium oxychloride, cerium chloride, cerium oxide and cerium sulfate.
  • the hydrothermal process used to prepare the zirconium metallate or titanium metallate ion exchange compositions of this invention involves forming a reaction mixture which in terms of molar ratios of the oxides is expressed by the formulae:
  • reaction mixture is prepared by mixing the desired sources of zirconium, silicon and optionally germanium, alkali metal and optional M metal in any order to give the desired mixture. It is also necessary that the mixture have a basic pH and preferably a pH of at least 8.
  • the basicity of the mixture is controlled by adding excess alkali hydroxide and/or basic compounds of the other constituents of the mixture. Having formed the reaction mixture, it is next reacted at a temperature of about 100°C to about 250°C for a period of about 1 to about 30 days in a sealed reaction vessel under autogenous pressure. After the allotted time, the mixture is filtered to isolate the solid product which is washed with deionized water, acid or dilute acid and dried. Numerous drying techniques can be utilized including vacuum drying, tray drying, fluidized bed drying. For example, the filtered material may be oven dried in air under vacuum.
  • the different structure types of the ZS molecular sieves and zirconium germanate molecular sieves have been given arbitrary designations of ZS-1 where the "1" represents a framework of structure type "1". That is, one or more ZS and/or zirconium germanate molecular sieves with different empirical formulas can have the same structure type.
  • the X-ray patterns presented in the following examples were obtained using standard X- ray powder diffraction techniques and reported in U.S. Patent No. 5,891,417.
  • the radiation source was a high-intensity X-ray tube operated at 45 Kv and 35 ma.
  • the diffraction pattern from the copper K-alpha radiation was obtained by appropriate computer based techniques.
  • Flat compressed powder samples were continuously scanned at 2° (2 ⁇ ) per minute.
  • Interplanar spacings (d) in Angstrom units were obtained from the position of the diffraction peaks expressed as 2 ⁇ where ⁇ is the Bragg angle as observed from digitized data.
  • Intensities were determined from the integrated area of diffraction peaks after subtracting background, "I 0 " being the intensity of the strongest line or peak, and "I" being the intensity of each of the other peaks.
  • the determination of the parameter 2 ⁇ is subject to both human and mechanical error, which in combination can impose an uncertainty of about ⁇ 0.4 on each reported value of 2 ⁇ . This uncertainty is, of course, also manifested in the reported values of the d-spacings, which are calculated from the ⁇ values. This imprecision is general throughout the art and is not sufficient to preclude the differentiation of the present crystalline materials from each other and from the compositions of the prior art.
  • the purity of a synthesized product may be assessed with reference to its X-ray powder diffraction pattern.
  • a sample is stated to be pure, it is intended only that the X-ray pattern of the sample is free of lines attributable to crystalline impurities, not that there are no amorphous materials present.
  • the crystalline compositions of the instant invention may be characterized by their X-ray powder diffraction patterns and such may have one of the X-ray patterns containing the d- spacings and intensities set forth in the following Tables.
  • the x-ray pattern for ZS- 1 , ZS-2, ZS- 6, ZS-7, ZS-8, and ZS-1 1 as reported in U.S. Patent No. 5,891 ,417, is as follows:
  • ZS The formation of ZS involves the reaction of sodium silicate and zirconium acetate in the presence of sodium hydroxide and water.
  • the reaction has typically been conducted in small reaction vessels on the order of 1-5 Gallons.
  • the smaller reaction vessels have been used to produce various crystalline forms of ZS including ZS-9.
  • the inventors recognized that the ZS-9 being produced in these smaller reactors had an inadequate or undesirably low cation exchange capacity (CEC).
  • CEC cation exchange capacity
  • the inventors have discovered that the use and proper positioning of a baffle-like structure in relation to the agitator within the crystallization vessel produces a ZS-9 crystal product exhibiting crystalline purity (as shown by XRD and FTIR spectra) and an unexpectedly high potassium exchange capacity.
  • cooling coils were positioned within the reactor to provide a baffle-like structure. The cooling coils were not used for heat exchange.
  • serpentine-type coils which snake along the inside wall of the reactor vessel.
  • the baffles and agitator improved the reaction conditions by creating forces within the reactor that lift the crystals within the vessel allowing for the necessary heat transfer and agitation to make a high purity form of ZS-9.
  • the baffles in combination with the agitator may be configured such that it provides sufficient lift throughout the entire volume regardless of the size of the reactor used. For example, if the reactor size is enlarged (e.g., 200 liter reactor) and the reaction volume is increased, the baffles will also be resized to accommodate the new reactor volume.
  • Figs. 11-12 show XRD and FTIR spectra of high purity ZS-9 crystals. As shown in Table 3 below, these crystals exhibit significantly higher levels of potassium exchange capacity (KEC) than the less pure ZS-9 compositions.
  • the ZS-9 crystals had a potassium exchange capacity of between 2.7 and 3.7 meq/g, more preferably between 3.05 and 3.35 meq/g.
  • ZS-9 crystals with a potassium exchange capacity of 3.1 meq/g have been manufactured on a commercial scale and have achieved desirable clinical outcomes. It is expected that ZS-9 crystals with a potassium exchange capacity of 3.2 meq/g will also achieve desirable clinical outcomes and offer improved dosing forms.
  • the targets of 3.1 and 3.2 meq/g may be achieved with a tolerance of ⁇ 15%, more preferably ⁇ 10%, and most preferably ⁇ 5%. Higher capacity forms of ZS-9 are desirable although are more difficult to produce on a commercial scale.
  • Such higher capacity forms of ZS-9 have elevated exchange capacities of greater than 3.5 meq/g, preferably greater than 4.0 meq/g, more preferably between 4.3 and 4.8 meq/g, even more preferably between 4.4 and 4.7 meq/g, and most preferably approximately 4.5 meq/g.
  • ZS-9 crystals having a potassium exchange capacity in the range of between 3.7 and 3.9 meq/g were produced in accordance with Example 13 below.
  • microporous compositions of this invention have a framework structure of octahedral Zr0 3 units, at least one of tetrahedral Si0 2 units and tetrahedral Ge0 2 units, and optionally octahedral M0 3 units.
  • This framework results in a microporous structure having an intracrystalline pore system with uniform pore diameters, i.e., the pore sizes are
  • the diameter of the pores can vary considerably from about 3 angstroms and larger.
  • the microporous compositions of this invention will contain some of the alkali metal templating agent in the pores. These metals are described as exchangeable cations, meaning that they can be exchanged with other (secondary) A' cations. Generally, the A exchangeable cations can be exchanged with A' cations selected from other alkali metal cations (K , Na , Rb , Cs ), alkaline earth cations (Mg , Ca , Sr , Ba ), hydronium ion or mixtures thereof. It is understood that the A' cation is different from the A cation.
  • the methods used to exchange one cation for another are well known in the art and involve contacting the microporous compositions with a solution containing the desired cation (usually at molar excess) at exchange conditions.
  • exchange conditions include a temperature of about 25°C to about 100° C and a time of about 20 minutes to about 2 hours.
  • the use of water to exchange ions to replace sodium ions with hydronium ions may require more time, on the order of eight to ten hours.
  • the particular cation (or mixture thereof) which is present in the final product will depend on the particular use and the specific composition being used.
  • One particular composition is an ion exchanger where the A' cation is a mixture of Na , Ca , Mg , a mixture of both Ca and Mg 2+ , and H + ions.
  • the Na-ZS-9 When ZS-9 is formed according to these processes, it can be recovered in the Na-ZS-9 form.
  • the sodium content of Na-ZS-9 is approximately 12 to 13% by weight when the manufacturing process is carried out at pH greater than 9.
  • the Na-ZS-9 is unstable in
  • the conversion of Na-ZS-9 to H-ZS-9 may be accomplished through a combination of water washing and ion exchange processes, i.e., ion exchange using a dilute strong acid, e.g., 0.1 M HCl or by washing with water. Washing with water will decrease the pH and protonate a significant fraction of the ZS, thereby lowering the weight fraction of Na in the ZS. It may be desirable to perform an initial ion exchange in strong acid using higher concentrations, so long as the protonation of the ZS will effectively keep the pH from dropping to levels at which the ZS decomposes. Additional ion exchange may be accomplished with washing in water or dilute acids to further reduce the level of sodium in the ZS.
  • a dilute strong acid e.g., 0.1 M HCl
  • the ZS made in accordance with the present invention exhibits a sodium content of below 12% by weight.
  • the sodium contents is below 9% by weight, more preferably the sodium content is below 6% by weight, more preferably the sodium content is below 3% by weight, more preferably the sodium content is in a range of between 0.05 to 3% by weight, and most preferably 0.01% or less by weight or as low as possible.
  • protonated (i.e., low sodium) ZS is prepared in accordance with these techniques, the potassium exchange capacity is lowered relative to the un-protonated crystals.
  • the ZS prepared in this way has a potassium exchange capacity of greater than 2.8.
  • the potassium exchange capacity is within the range of 2.8 to 3.5 meq/g, more preferably within the range of 3.05 and 3.35 meq/g, and most preferably about 3.2 meq/g.
  • a potassium exchange capacity target of about 3.2 meq/g includes minor fluctuations in measured potassium exchange capacity that are expected between different batches of ZS crystals.
  • the ion exchanger in the sodium form e.g., Na-ZS-9
  • the ion exchanger in the sodium form is effective at removing excess potassium ions from a patient's gastrointestinal tract in the treatment of hyperkalemia.
  • hydronium ions replace sodium ions on the exchanger leading to an unwanted rise in pH in the patient's stomach and gastrointestinal tract.
  • the hydronium form typically has equivalent efficacy as the sodium form for removing potassium ions in vivo while avoiding some of the disadvantages of the sodium form related to pH changes in the patient's body.
  • the hydrogenated form has the advantage of avoiding excessive release of sodium in the body upon administration. This can mitigate edema resulting from excessive sodium levels, particularly when used to treat acute conditions.
  • patient who are administered the hydronium form to treat chronic conditions will benefit from the lower sodium levels, particularly patients at risk for congestive heart failure. Further, it is believed that the hydronium form will have the effect of avoiding an undesirable increase of pH in the patient's urine.
  • ZS compositions lacking added calcium can serve to withdraw excess calcium from patients which makes these compositions useful in the treatment of hyperkalemia in hypercalcemic patents as well as for the treatment of
  • compositions prepared according to the process above are typically very low, i.e., below 1 ppm.
  • the present inventors have found that treatment of hyperkalemia with these compositions is also associated with removal of significant quantities of calcium from the patient's body. Therefore, these compositions are particularly useful for the treatment of hypercalcemic patients or hypercalcemic patients suffering from hyperkalemic.
  • the compositions of the present invention are prepared by pre-loading the above- described ZS compositions with calcium ions. The pre-loading of the compositions with calcium results in a composition that will not absorb calcium when administered to patients.
  • the pre-loading of ZS with calcium (and/or magnesium) is accomplished by contacting the ZS with a dilute solution of either calcium or magnesium ions, preferably having a calcium or magnesium concentration range of about 10-100 ppm.
  • the pre-loading step can be accomplished simultaneously with the step of exchanging hydronium ions with sodium ions as discussed above.
  • the pre-loading step can be accomplished by contacting ZS crystals at any stage of their manufacture with a calcium or magnesium containing solution.
  • the ZS compositions comprise calcium or magnesium levels ranging from 1 to 100 ppm, preferably from 1 to 30 ppm, and more preferably between 5 and 25 ppm.
  • composition of the present invention may also be prepared by pre-loading the ZS with a dilute solution of magnesium ion or a mixture of both calcium and magnesium according to the method described above.
  • the magnesium concentration is in the range of about 10-100 ppm, preferably 1-30 ppm, and more preferably 5-25 ppm.
  • Pre-loaded ZS compositions with a mixture of both calcium and magnesium are at a ratio of calcium to magnesium in a range of l : 10 to 10: 1, preferably 1 :5 to 5: 1, or more preferably 1 :2 to 2:1 , wherein the final
  • the pre-loaded ZS regardless of the divalent cation used, does not affect the potassium exchange concentration of the composition.
  • the skilled practitioner will be capable of determining the appropriate concentrations of the divalent cation such that the potassium exchange rates of the ZSs are not effected.
  • the pre-loading of ZS does not result in a reduction in potassium absorption capacity and therefore does not detract from the use of these compositions in the treatment of hyperkalemia. It is believed that due to their size, divalent cations, such as calcium or magnesium ions, do not fully penetrate the pores of the ZS. Rather, the loaded divalent cations remain only on the surface of the ZS. The added divalent cations result in a composition that does not absorb calcium from the patient's body and therefore is preferred for clinical use in the treatment of hyperkalemia.
  • protonated ZS may be linked to hydroxyl-loaded anion exchanger such as zirconium oxide (OH-ZO), which help in the removal of sodium, potassium, ammonium, hydrogen and phosphate.
  • OH-ZO zirconium oxide
  • the hydrogen released from the protonated ZS and hydroxide released from OH-ZO combine to form water, thus diminishing the concentration of "counter-ions" which diminish binding of other ions.
  • the binding capacity of the cation and anion exchangers should be increased by administering them together.
  • ZS of this form are useful for the treatment of many different types of diseases.
  • the compositions are used to remove sodium, potassium, ammonium, hydrogen and phosphate from the gut and from the patient with kidney failure.
  • the ZS-9 crystals have a broad particle size distribution. It has been theorized that small particles, less than 3 microns in diameter, could potentially be absorbed into a patient's bloodstream resulting in undesirable effects such as the accumulation of particles in the urinary tract of the patient, and particularly in the patent's kidneys.
  • the commercially available ZSs are manufactured in a way that some of the particles below 1 micron are filtered out. However, it has been found that small particles are retained in the filter cake and that elimination of particles having a diameter less than 3 microns requires the use of additional screening techniques. The inventors have found that screening can be used to remove particles having a diameter below 3 microns and that removal of such particles is beneficial for therapeutic products containing the ZS compositions of the invention.
  • ZS compositions that have been subject to screening techniques exhibit a desired particle size distribution that avoids potential complications involving the therapeutic use of ZS. In general, the size distribution of particles is not critical, so long as excessively small particles are removed.
  • the ZS compositions of the invention exhibit a median particle size greater than 3 microns, and less than 7% of the particles in the composition have a diameter less than 3 microns.
  • less than 5% of the particles in the composition have a diameter less than 3 microns, more preferably less than 4% of the particles in the composition have a diameter less than 3 microns, more preferably less than 3% of the particles in the composition have a diameter of less than 3 microns, more preferably less than 2% of the particles in the composition have a diameter of less than 3 microns, more preferably less than 1% of the particles in the composition have a diameter of less than 3 microns, more preferably less than 0.5% of the particles in the composition have a diameter of less than 3 microns.
  • none of the particles or only trace amounts have a diameter of less than 3 microns.
  • the median particle size is preferably greater than 3 microns and particles reaching a sizes on the order of 1 ,000 microns are possible for certain applications.
  • the median particle size ranges from 5 to 1000 microns, more preferably 10 to 600 microns, more preferably from 15 to 200 microns, and most preferably from 20 to 100 microns.
  • the particle screening can be conducted before, during, or after an ion exchange process such as described above whereby the sodium content of the ZS material is lowered below 12%.
  • the lowering of sodium content to below 3% can occur over several steps in conjunction with screening or can occur entirely before or after the screening step.
  • Particles having a sodium content below 3% may be effective with or without screening of particles sizes as described herein.
  • the desired particle size distribution may be achieved using a granulation or other agglomeration technique for producing appropriately sized particles.
  • the ZS compositions may further comprise atoms or molecules attached onto their surfaces to produced grafted crystals.
  • the grafted atoms or molecules are attached to the surface of the ZS, preferably through stable covalent bonds.
  • an organosilicate moiety is grafted onto the surface of the ZS composition through reacting active groups such as silanols ( ⁇ Si-0-H) on the surface of crystals. This may be accomplished, for example by using aprotic solvents.
  • an alkoxysilane may be grafted and would require the use of a corresponding alcohol to perform the reaction. Identifying free silanol groups on the surface can done through, for example by, Infrared spectroscopy.
  • the ZS compositions may further comprise tagging the composition with radioactive isotopes, such as but not limited to C or Si.
  • the ZS compositions may also comprise non-exchangeable atoms, such as isotopes of Zr, Si, or O, which may be useful in mass-balance studies. It is also within the scope of the invention that these microporous ion exchange compositions can be used in powder form or can be formed into various shapes by means well known in the art. Examples of these various shapes include pills, extrudates, spheres, pellets and irregularly shaped particles.
  • the various forms can be packaged in a variety of known containers. These might include capsules, plastic bags, pouches, packets, sachets, dose packs, vials, bottles, or any other carrying device that is generally known to one of skill in the art.
  • the various forms can be packaged in a variety of known containers. These might include capsules, plastic bags, pouches, packets, sachets, dose packs, vials, bottles, or any other carrying device that is generally known to one of skill in the art.
  • the microporous ion exchange crystals of this invention may be combined with other materials to produce a composition exhibiting a desired effect.
  • the ZS compositions may be combined with foods, medicaments, devices, and compositions that are used to treat a variety of diseases.
  • the ZS compositions of the present invention may be combined with toxin reducing compounds, such as charcoal, to expedite toxin and poison removal.
  • the ZS crystals may exist as a combination of two or more forms of ZS of ZS-1 to ZS- 11.
  • the combination of ZS may comprise ZS-9 and ZS- 11 , more preferably ZS-9 and ZS-7, even more preferably ZS-9, ZS-11, and ZS-7.
  • the ZS composition may comprise a blend or mixture of ZS-9, wherein ZS-9 is present at greater than at least 40%, more preferably greater than at least 60%, even more preferably greater than or equal 70%, where the remainder may comprise mixtures of other forms of ZS crystals (i.e., ZS-1 to ZS-11) or other amorphous forms.
  • the blend of ZS-9 may comprise greater than about between 50%> to 75% ZS-9 crystals and greater than about 25% to about 50% ZS-7 crystals with the remainder being other forms of ZS crystals, wherein the remainder of the ZS crystals does not include ZS-8 crystals.
  • compositions have particular utility in adsorbing various toxins from fluids selected from bodily fluids, dialysate solutions, and mixtures thereof.
  • bodily fluids will include but not be limited to blood and gastrointestinal fluids.
  • bodily is meant any mammalian body including but not limited to humans, cows, pigs, sheep, monkeys, gorillas, horses, dogs, etc. The instant process is particularly suited for removing toxins from a human body.
  • the zirconium metallates can also be formed into pills or other shapes which can be ingested orally and pickup toxins in the gastrointestinal fluid as the ion exchanger transits through the intestines and is finally excreted.
  • the ZS compositions may be made into wafer, a pill, a powder, a medical food, a suspended powder, or a layered structure comprising two or more ZS.
  • the shaped articles may be coated with various coatings which will not dissolve in the stomach, but dissolve in the intestines.
  • the ZS may be shaped into a form that is subsequently coated with an enteric coating or embedded within a site specific tablet, or capsule for site specific delivery.
  • compositions are synthesized with a variety of exchangeable cations ("A"), it is preferred to exchange the cation with secondary cations ( ⁇ ') which are more compatible with blood or do not adversely affect the blood.
  • preferred cations are sodium, calcium, hydronium and magnesium.
  • Preferred compositions are those containing sodium and calcium, sodium, calcium and magnesium sodium, and hydronium ions, sodium, magnesium, and hydronium ions, or sodium, calcium and hydronium ions, sodium, magnesium, and/or magnesium, or sodium calcium and/or magensium, and hydronium ions.
  • the relative amount of sodium and calcium and/or magnesium can vary considerably and depends on the microporous composition and the concentration of these ions in the blood. As discussed above, when sodium is the exchangeable cation, it is desirable to replace the sodium ions with hydronium ions thereby reducing the sodium content of the composition.
  • ZS crystals as described in related U.S. Application 13/371,080, which is incorporated by reference in its entirety, have increased cation exchange capacities or potassium exchange capacity. These increased capacity crystals may also be used in accordance with the present invention.
  • the dosage utilized in formulating the pharmaceutical composition in accordance to the present invention will be adjusted according to the cation exchange capacities determined by those of skill in the art. Accordingly, the amount of crystals utilized in the formulation will vary based on this determination. Due to its higher cation exchange capacity, less dosage may be required to achieve the same effect.
  • compositions of the present invention may be used in the treatment of diseases or conditions relating to elevated serum potassium levels. These disease may include for example chronic or acute kidney disease, chronic, acute or sub-acute hyperkalemia.
  • diseases or conditions may include for example chronic or acute kidney disease, chronic, acute or sub-acute hyperkalemia.
  • the product of the present invention is administered at specific potassium reducing dosages.
  • the administered dose ranges from approximately 1.25-15 grams (-18-215 mg/Kg/day, preferably from approximately 500 to 1,000 mg/Kg/day, and most preferably approximately 10 grams (-140 mg/Kg/day) three times a day.
  • the total administered dose of the composition may range from approximately 15-45 gram (-215-640 mg/Kg/day), preferably 24-36 grams (-350- 520mg/Kg/day), and more preferably 30 grams (-400 mg/Kg/day).
  • the composition of the present invention is capable of decreasing the serum potassium levels to near normal levels of approximately 3.5-5 mmol/L.
  • the molecular sieves of the present product are capable of specifically removing potassium without affecting other electrolytes, (i.e., no hypomagnesemia or no hypocalcemia). The use of the present product or composition is accomplished without the aid of laxatives or other resins for the removal of excess serum potassium.
  • the dosages will typically be lower due to the increased effectiveness of the compositions for lowering potassium levels in a patient.
  • the dose preferably ranges from approximately 0.7 to 800 mg/Kg/day, more preferably from approximately 280 to 500 mg/Kg/day, and most preferably approximately 390 mg/Kg/day.
  • a typical daily dose for treatment of acute hyperkalemia, depending on the potassium exchange capacity, in a human patient will range from approximately 50 mg to 33 g per day, more preferably from approximately 1 mg to 30 g per day, more preferably 3 to 9 g per day, and most preferably approximately 3 g per day.
  • the dose preferably ranges from 0.25 to 55 mg/Kg/day, more preferably from 5 to 40 mg/Kg/day, and most preferably approximately 30 mg/Kg/day.
  • a typical daily dose for treatment of chronic hyperkalemia in a human patient will range from approximately 0.020 to 5 g per day, more preferably from 0.05 to 0.7 g per day, and most preferably approximately 0.5 g per day.
  • Acute hyperkalemia requires an immediate reduction of serum potassium levels to normal or near normal levels.
  • Molecular sieves of the present invention which have a KEC in the range of approximately 1.3-2.5 meq/g would be capable of lowering the elevated levels of potassium to within normal range in a period of about 1-8 hours after administration.
  • the product of the present invention is capable of lowering the elevated levels in about at least 1, 2, 4, 6, 8, 10 hours after administration.
  • the dose required to reduce the elevated potassium levels may be in the range of about 5-15 grams, preferably 8-12 grams, more preferably 10 grams.
  • Molecular sieves having a higher KEC in the range of approximately 2.5- 4.7 meq/g would be more efficient in absorbing potassium.
  • the dose required to reduce the elevated potassium levels may be in the range of about 1.25-6 grams.
  • the schedule of dose administration may be at least once daily, more preferably three times a day.
  • compositions comprising molecular sieves having KEC in the range of approximately 2.5-4.7 meq/g will be scheduled for a dose in the range of approximately 1-5 grams, preferably 1.25-5 grams, preferably 2.5-5 grams, preferably 2-4 grams, more preferably 2.5 grams.
  • compositions comprising molecular sieves having a KEC in the range of approximately 2.5-4.7 meq/g will receive less and will be scheduled for a dose in the range of approximately 0.4-2.5 grams, preferably 0.8-1.6 grams, preferably 1.25-5 grams, preferably 2.5-5 grams, more preferably 1.25 grams. Compliance in this subset of patients is a major factor in maintaining normal potassium levels. As such, dosing schedule will therefore be an important consideration. In one embodiment, the dose will be given to patients at least three times a day, more preferably once a day.
  • composition or product of the present invention may be formulated in a manner that is convenient for administration.
  • the composition of the present invention may be formulated as a tablet, capsule, powder, granule, crystal, packet, or any other dose form that is generally known to one of skill in the art.
  • the various forms can be formulated as individual dosages comprising between 5-15 grams, preferably 8-12 grams, or more preferably 10 grams for multiple administrations per day, week or month; or they may be formulated as a single dosage comprising between 15-45 grams, preferably 24-36 grams, or more preferably 30 grams.
  • the individual dosage form can be at least greater than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, or 40 grams.
  • the dosage form is tablet, it may be formulated as a granule, granule-like, or as an extended release form. Capsules may be formulated for administration three times a day, as a sprinkle, an extended release sprinkle, or a dose pack. Powders may be formulated for reconstitution, contained in plastic bags or packets. Those of skill in the art will recognize that the above description of dosage forms is not limiting and that other dosage forms for solids may be used to administer the product or composition of the present invention.
  • the administration of the composition of the present invention at the specifically described dosing of approximately 10 grams (-140 mg/Kg/day) three times a day (i.e., 30 grams (-400 mg/Kg/day) total) is capable of reducing potassium levels in the serum for an extended duration of time.
  • the inventors have found that when the product or composition of the present invention is administered at a dosage of approximately 10 grams three times a day, the effects of lowering serum potassium levels to within normal levels is sustained for 5 days after 2 days of acute therapy. It was expected, however, that the product of the present invention would be expelled in a relatively quick manner.
  • the ZS of the present invention may be modified and/or combined with other drugs or treatments if multiple conditions or diseases are present in a subject.
  • a subject may present with both hyperkalemia and chronic kidney disease, in which Na-ZS compositions may be used.
  • the ZS compositions used to treat chronic kidney disease may further comprise sodium bicarbonate in combination with protonated forms of the ZS.
  • subjects presenting with hyperkalemia and chronic heart failure may require the use of protonated ZS compositions.
  • the treatment of hyperkalemia and chronic heart disease will require no more than 10% sodium present in the ZS, more preferably less than 2% sodium.
  • the ZS described herein may be further combined with activated carbon.
  • the activated carbon has the effect of attracting organic molecules circulating within the system of a subject. See, e.g., HSGD Haemosorbents for Medical Device Applications, Nikolaev V.G. Presentation, London.
  • the combination of activated carbon with a ZS will act as a combination product having the ability to remove both excess potassium, and organic molecules.
  • the activated carbon will comprise a multiplicity of adsorption pores of ranging from about 8 angstroms to about 800 angstroms in diameter, preferably at least about 50 angstroms in diameter.
  • the ZS combined with activated carbon of the present invention will be useful in the treatment of many diseases and/or conditions requiring the removal of excess organic materials, such as but not limited to, lipids, proteins, and toxins.
  • the carbon containing ZS compositions of the present invention will be useful in the removal of pyrimidines, methylguanidines, guanidines, o-hydroxyhippuric acid, p- hydroxyhippuric acid, parathormone, purines, phenols, indols, pesticides, carcinogenic heterocyclic amines, conjugates of ascorbic acids, trihalomethanes, dimethylarginine, methylamines, organic chloramines, polyamines, or combinations thereof.
  • the activated carbon combined with ZS will also be useful in adsorbing elevated levels of bile acids, albumin, ammonia, creatinine and bilirubin.
  • the composition may be further coated with an albumin layer, a lipid layer, a DNA layer, a heparin layer, resulting in additional adsorption efficiencies ranging from about 12% to about 35%.
  • the activated carbon and ZS compositions will be useful in treating a subject presenting with multiple diseases or conditions, such as hyperkalemia, acute and chronic esogastritis, acute and chronic intestinal catarrhus, hyperacid gastritis, summer diarrhea, catarrhal jaundice, food related toxicoinfections, kidney disease, dysentery, choloera, typhoid, intestinal bacilli-carrier, heartburn, nausea, acute viral hepatitis, chronic active hepatitis and cirrhosis, concomitant hepatitis, mechanical jaundice, hepato-renal failure, hepatic coma, or combinations thereof.
  • diseases or conditions such as hyperkalemia, acute and chronic esogastritis, acute and chronic intestinal catarrhus, hyperacid gastritis, summer diarrhea, catarrhal jaundice, food related toxicoinfections, kidney disease, dysentery, choloera, typhoid, intestinal bacilli-
  • the ZS compositions described herein may be used in a variety of methods comprising administering to a subject in need thereof a composition described herein to remove excess levels of potassium.
  • the method may include the administration of a combination of the ZS described herein and may further comprise additional compositions to aid in the removal of potassium while simultaneously removing other substances, such as but not limited to toxins, proteins, or ions, from the subject.
  • a solution was prepared by mixing 2058 g of colloidal silica (DuPont Corp. identified as LudoxTM AS-40), 2210 g of KOH in 7655 g H 2 0. After several minutes of vigorous stirring 1471 g of a zirconium acetate solution (22.1 wt. % Zr0 2 ) were added. This mixture was stirred for an additional 3 minutes and the resulting gel was transferred to a stainless steel reactor and hydrothermally reacted for 36 hours at 200°C. The reactor was cooled to room temperature and the mixture was vacuum filtered to isolate solids which were washed with deionized water and dried in air.
  • the solid reaction product was analyzed and found to contain 21.2 wt. % Si, 21.5 wt. % Zr, K 20.9 wt. % K, loss on ignition (LOI) 12.8 wt. %, which gave a formula of
  • a solution was prepared by mixing 121.5 g of colloidal silica (DuPont Corp. identified as Ludox ® AS-40), 83.7 g of NaOH in 1051 g H 2 0. After several minutes of vigorous stirring 66.9 g zirconium acetate solution (22.1 wt. % Zr0 2 ) was added. This was stirred for an additional 3 minutes and the resulting gel was transferred to a stainless steel reactor and hydrothermally reacted with stirring for 72 hours at 200°C. The reactor was cooled to room temperature and the mixture was vacuum filtered to isolate solids which were washed with deionized water and dried in air.
  • the solid reaction product was analyzed and found to contain 22.7 wt. % Si, 24.8 wt. % Zr, 12.8 wt. % Na, LOI 13.7 wt. %, which gives a formula Na 2 .oZrSi3.o0 9 .o *3.5H 2 0. This product was identified as sample B.
  • a solution (60.08 g) of colloidal silica (DuPont Corp. identified as Ludox ® AS-40) was slowly added over a period of 15 minutes to a stirring solution of 64.52 g of KOH dissolved in 224 g deionized H 2 0. This was followed by the addition of 45.61 g zirconium acetate (Aldrich 15-16 wt. % Zr, in dilute acetic acid). When this addition was complete, 4.75 g hydrous Nb 2 0 5 (30 wt. % LOI) was added and stirred for an additional 5 minutes. The resulting gel was transferred to a stirred autoclave reactor and hydrothermally treated for 1 day at 200°C. After this time, the reactor was cooled to room temperature, the mixture was vacuum filtered, the solid washed with deionized water and dried in air.
  • colloidal silica DuPont Corp. identified as Ludox ® AS-40
  • the solid reaction product was analyzed and found to contain 20.3 wt. % Si, 15.6 wt. % Zr, 20.2 wt. % K, 6.60 wt. % Nb, LOI 9.32 wt. %, which give a formula of K2.14Zro.71Nbo.29 Si 3 0 9 .2*2.32H 2 0.
  • batch-wise ion exchange with a dilute strong acid is capable of reducing the sodium content of a NA-ZS-9 composition to within a desired range.
  • water washing is capable of reducing the sodium content of a NA-ZS-9 composition to within a desired range.
  • Crystals of ZS-9 were subject to screening to remove small diameter particles.
  • the resulting particle size distribution of the ZS-9 crystals screened using different size screens was analyzed.
  • the fraction of particles having a diameter below 3 microns can be lowered and eliminated using an appropriate mesh size screen. Without screening, approximately 2.5% percent of the particles had a diameter of below 3 microns. See Fig. 5.
  • the fraction of particles having a diameter below 3 microns was reduced to approximately 2.4%.
  • Fig. 635 mesh screen the fraction of particles having a diameter below 3 microns was reduced to approximately 2.4%.
  • Fig. 635 mesh screen the fraction of particles having a diameter below 3 microns was reduced to approximately 2.4%.
  • Fig. 635 mesh screen the fraction of particles having a diameter below 3 microns was reduced to approximately 2.4%.
  • Fig. 635 mesh screen Upon screening with a 635 mesh screen, the fraction of particles having a diameter below 3 microns was reduced to approximately 2.4%.
  • Fig. 635 mesh screen the
  • ZS-9 that provide little or no particles below 3 microns. It will be appreciated that ZS-9 according to Example 5 or H-ZS-9 according to Examples 6 and 7 may be screened as taught in this example to provide a desired particle size distribution. Specifically, the preferred particle size distributions disclosed herein may be obtained using the techniques in this example for both ZS-9 and H-ZS-9. EXAMPLE 10
  • Plasma samples for analysis of serum chemistry, hematology, coagulation and urinalysis parameters were collected pretest (Day -1) and Day 13.
  • Ophthalmologic examinations were performed pretest (Day -6/7) and on Day 7 (females) or 8 (males).
  • Electrocardiographic assessments were performed pretest (Day -1) and on Day 11.
  • necropsy examinations were performed, protocol specified organ weights were weighed, and selected tissues were microscopically examined.
  • Crystals were not identified in group 2 or 4 females or in any ZS-9 treated males.
  • urinary pH was elevated compared to control and it was postulated that the change in urinary pH and/or urinary composition affected urine solute solubility resulting in crystal formation that caused urinary tract irritation and/or increased susceptibility to urinary tract infections (UTIs).
  • UTIs urinary tract infections
  • Crystals of ZS-9 are prepared and designated "ZS-9 Unscreened.” Screening in accordance with the procedures of Example 10 is conducted on a sample of ZS-9 crystals and the screened sample is designated "ZS-9 >5 ⁇ .” Another sample of Crystals of ZS-9 undergo an ion exchange in accordance with the procedures of Example 6 above and are then screened in accordance with the procedures of Example 10. The resulting H-ZS-9 crystals are designated "ZS-9 + >5 ⁇ .”
  • the following 14-day study is designed to show the effect of particle size and particle form on the urinary pH and presence of crystals in the urine.
  • the compounds above are administered to beagles orally by mixing with wet dog food.
  • the regimen is administered 3 times a day at 6 hour intervals over a 12 hour period in the following manner:
  • Dose Formulation Analysis Dose records will be used to confirm dosing. Weig of any remaining wet food will be recorded.
  • ZS-9 crystals were prepared by reaction in a standard 5-G crystallization vessel.
  • the reactants were prepared as follows. A 22-L Morton flask was equipped with an overhead stirrer, thermocouple, and an equilibrated addition funnel. The flask was charged with deionized water (3.25 L). Stirring was initiated at approximately 100 rpm and sodium hydroxide (1091 g NaOH) was added to the flask. The flask contents exothermed as the sodium hydroxide dissolved. The solution was stirred and cooled to less than 34 °C. Sodium silicate solution (5672.7 g) was added. To this solution was added zirconium acetate solution (3309.5 g) over 43 minutes. The resulting suspension was stirred for another 22 minutes. Seed crystals of ZS-9 (223.8 g) were added to the reaction vessel and stirred for approximately 17 minutes.
  • the mixture was transferred to a 5-G Parr pressure vessel with the aid of deionized water (0.5 L).
  • the vessel had smooth walls and a standard agitator.
  • the reactor did not have a cooling coil present.
  • the vessel was sealed and the reaction mixture was stirred at approximately 275- 325 rpm and heated to 185 +/- 10 °C over 4 hours, then held at 184-186 °C and soaked for 72 hours. Finally, the reactants were then cooled to 80 °C over 12.6 hours.
  • the resulting white solid was filtered with the aid of deionized water (18L).
  • the solids were washed with deionized water (125 L) until the pH of the eluting filtrate was less than 11 (9.73).
  • the wet cake was dried in vacuo (25 inches Hg) for 48 hours at 95-105 °C to give 2577.9 g (107.1%) of ZS-9 as a white solid.
  • the XRD plot of the ZS-9 obtained in this example is shown in Fig. 10.
  • the FTIR plot of this material is shown in Fig. 11.
  • These XRD and FTIR spectra are characterized by the presence of absorption peaks typically associated with the ZS-11 crystalline form.
  • the peaks that are associated with ZS-9 exhibit significant spreading due to crystal impurities (e.g. the presence of ZS-11 crystals in a ZS-9 composition).
  • the FTIR spectra shows significant absorption around 764 and 955 cm "1 .
  • the XRD plot for this example exhibits significant noise and poorly defined peaks at 2-theta values of 7.5, 32, and 42.5.
  • the reactants were prepared as follows. A 22-L Morton flask was equipped with an overhead stirrer, thermocouple, and an equilibrated addition funnel. The flask was charged with deionized water (8,600 g, 477.37 moles). Stirring was initiated at approximately 145-150 rpm and sodium hydroxide (661.0 g, 16.53 moles NaOH, 8.26 moles Na20) was added to the flask. The flask contents exothermed from 24 °C to 40 °C over a period of 3 minutes as the sodium hydroxide dissolved. The solution was stirred for an hour to allow the initial exotherm to subside.
  • the mixture was transferred to a 5-G Parr pressure vessel Model 4555 with the aid of deionized water (500g, 27.75 moles).
  • the reactor was fitted with a cooling coil having a serpentine configuration to provide a baffle-like structure within the reactor adjacent the agitator.
  • the cooling coil was not charged with heat exchange fluid as it was being used in this reaction merely to provide a baffle-like structure adjacent the agitator.
  • the vessel was sealed and the reaction mixture was stirred at approximately 230-235 rprn and heated from 21 °C to 140-145 °C over 7.5 hours and held at 140-145 °C for 10.5 hours, then heated to 210-215 °C over 6.5 hours where the maximum pressure of 295-300 psi was obtained, then held at 210-215 °C for 4 1.5 hours. Subsequently, the reactor was cooled to 45 °C over a period of 4.5 hours. The resulting white solid was filtered with the aid of deionized water (1.0 KG). The solids were washed with deionized water (40 L) until the pH of the eluting filtrate was less than 1 1 (10.54). A representative portion of the wet cake was dried in vacuo (25 inches Hg) overnight at 100 °C to give 1 ,376 g (87.1%) of ZS-9 as a white solid.
  • the XRD plot of the ZS-9 obtained is shown in Fig. 12.
  • the FTIR plot of this material is shown in Fig. 13.
  • These XRD and FTIR spectra when compared to those for Example 12 (Figs. 10-1 1), exhibited well-delineated peaks without spreading and the absence of peaks associated with crystalline forms other than ZS-9 (e.g., ZS-1 1 peaks).
  • This example illustrates how the presence of a baffle-like structure within the reactor drastically and unexpectedly improves the quality of the thus obtained crystals.
  • baffles provide added turbulence which lifts the solids (i.e., crystals) and results in a more even suspension of crystals within the reaction vessel while the reaction is ongoing. This improved suspension allows for more complete reaction to the desired crystalline form and reduces the presence of unwanted crystalline forms of ZS in the end product.
  • the potassium exchange capacity (KEC) of ZS (ZS-9) was determined according to the following protocol.
  • This test method used a HPLC capable of gradient solvent introduction and cation exchange detection.
  • the column was an IonPac CS 12A, Analytical (2 x 250 mm). The flow rate was 0.5 mL/minute with a run time of approximately 8 minutes. The column temperature was set to 35 °C. The injection volume was 10 ⁇ , and the needle wash was 250 ⁇ . The pump was operated in Isocratic mode and the solvent was DI water. A stock standard was prepared by accurately weighing and recording the weight of about 383 mg of potassium chloride (ACS grade), which was transferred into a ⁇ - ⁇ , plastic volumetric flask. The material was dissolved and diluted to volume with diluent followed by mixing.
  • ACS grade potassium chloride
  • the stock standard had a K + concentration of 2000 ppm (2mg/mL).
  • Samples were prepared by accurately weighing, recording, and transferring about 112 mg of ZS-9 into a 20 mL plastic vial. 20.0 mL of the 2000 ppm potassium stock standard solution was pipetted into the vial and the container was closed. The sample vials were placed onto a wrist action shaker and were shook for at least 2 hours but not more than 4 hours. The sample preparation solution was filtered through a 0.45 pm PTFE filter into a plastic container. 750 pL of the sample solution was transferred into a 100-mL plastic volumetric flask. The sample was diluted to volume with DI water and mixed. The initial K + concentration was 15 ppm (15 ⁇ g/mL).
  • Fig. 14 shows an example of the blank solution chromatogram.
  • Fig. 15 shows an example of the assay standard solution chromatogram.
  • Fig. 16 shows an exemplary sample chromatogram.
  • the potassium exchange capacity was calculated using the following formula:
  • KEC is the potassium exchange capacity in mEq/g.
  • the initial concentration of potassium (ppm) is IC.
  • the final concentration of potassium (ppm) is FC.
  • the equivalent weight (atomic weight/valence) is Eq wt.
  • the volume (L) of standard in sample preparation is V.
  • the weight of ZS-9 (mg) used for sample preparation is Wt spl .
  • the percent (%) of water content (LOD) is % water.
  • the inventors have designed a reactor for larger-scale production of high purity, high- KEC ZS-9 crystals. Large-scale reactors typically utilize a jacket for achieving heat transfer to the reaction chamber rather than coils suspended within the reaction chamber.
  • a conventional 200-L reactor 100 is shown in Fig. 17.
  • the reactor 100 has smooth walls and an agitator 101 extending into the center of the reaction chamber.
  • the reactor 100 also has a thermowell 102 and a bottom outlet valve 103.
  • the inventors have designed an improved reactor 200, Fig. 18, which also has an agitator 201 , thermowell 202, and bottom outlet valve 203.
  • the improved reactor 200 has baffle structures 204 on its sidewalls, which in combination with the agitator 201 provide significant lift and suspension of the crystals during reaction and the creation of high purity, high KEC ZS-9 crystals.
  • the improved reactor can also include a cooling or heating jacket for controlling the reaction temperature during crystallization in addition to the baffle structures 204.
  • the details of an exemplary and non-limiting baffle design is shown in Fig. 19.
  • the reactor has a volume of at least 20-L, more preferably 200-L or more, or within the range of 200- L to 30,000-L.
  • microporous ZS compositions disclosed herein have been found to absorb a significant amount of calcium from the patients body during treatment for hyperkalemia.
  • the compositions of Examples 1-9 and 12-13 are administered to hypercalcemic patients who are being treated for hyperkalemia.
  • the administration of these compositions to hypercalcemic patients suffering from hyperkalemia reduces both potassium and calcium levels in the patient.
  • compositions of Examples 1-9 and 12-13 are further processed to load the compositions with calcium, magnesium or mixtures of both calcium and magnesium.
  • the crystals of ZS of Examples 1-9 and 12-13 are obtained.
  • the crystals are then subject to an ion exchange process by contacting the crystals with a solution containing calcium ions, magnesium ions, or both calcium and magnesium at a concentration of between 10 and 100 ppm.
  • the resultant ZS compositions are effective at absorbing potassium while avoiding the absorption of excess calcium.
  • ZS crystals are contacted with calcium solutions having calcium concentrations of 30 ppm, 45 ppm, and 60 ppm.
  • the amount of calcium uptake is determined for each concentration after the saturation step in addition to determining a baseline level for each concentration prior to saturation.
  • the supernatant is pulled off and replaced with an equal volume of USP grade water and agitated for 20 minutes. This step is conducted twice. After completion of the second wash step, the water is removed and the sample is centrifuged at 3000 rpm for 5 minutes. Then the ZS crystal samples are placed in an oven at 75°C until dry, approximately 2 hours. Once the samples are dry, they are prepared as in Example 14 to determine the potassium exchange capacity. The amount of unbound calcium is determined as well.
  • ZS crystals are contacted with magnesium solutions having magnesium at concentrations of 30 ppm, 45 ppm, and 60 ppm.
  • the amount of calcium uptake is determined for each concentration after the saturation step in addition to determining a baseline level for each concentration prior to saturation.
  • the supernatant is pulled off and replaced with an equal volume of USP grade water and agitated for 20 minutes. This step is conducted twice. After completion of the second wash step, the water is removed and the sample is centrifuged at 3000 rpm for 5 minutes. Then the ZS crystal samples are placed in an oven at 75°C until dry, approximately 2 hours. Once the samples are dry, they are prepared as in Example 14 to determine the potassium exchange capacity. The amount of unbound magnesium is determined as well.
  • ZS crystals are contacted with a solution comprising both calcium and magnesium (at a ratio range of 1 : 10 to 10: 1), where the solution has a final calcium and magnesium concentration of 30 ppm, 45 ppm, and 60 ppm.
  • the amount of calcium uptake is determined for each concentration after the saturation step in addition to determining a baseline level for each concentration prior to saturation.
  • the supernatant is pulled off and replaced with an equal volume of USP grade water and agitated for 20 minutes. This step is conducted twice. After completion of the second wash step, the water is removed and the sample is centrifuged at 3000 rpm for 5 minutes. Then the ZS crystal samples are placed in an oven at 75°C until dry, approximately 2 hours. Once the samples are dry, they are prepared as in Example 14 to determine the potassium exchange capacity. The amount of unbound calcium and magnesium is determined as well.
  • the crystals of ZS of Examples 1-9 and 12-13 are administered to hypercalcemic patients to treat hyperkalemia. These compositions reduce levels of calcium and potassium in the patients.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
PCT/US2013/050071 2012-07-11 2013-07-11 Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia WO2014011876A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
BR112015000636A BR112015000636A2 (pt) 2012-07-11 2013-07-11 silicato de zircônio microporoso para o tratamento de hipercalemia em pacientes hipercalcêmicos e composições contendo cálcio melhoradas para o tratamento de hipercalemia
IN201KON2015 IN2015KN00201A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-07-11 2013-07-11
HK16103833.7A HK1215861A1 (zh) 2012-07-11 2013-07-11 用於治疗高钙血症患者高钾血症的微孔硅酸锆以及用於治疗高钾血症的改进的含钙组合物
HK15109434.8A HK1209029A1 (en) 2012-07-11 2013-07-11 Zirconium silicate for treatment of hyperkalemia
MX2015000381A MX2015000381A (es) 2012-07-11 2013-07-11 Silicato de zirconio microporoso para el tratamiento de la hipercalemia en pacientes hipercalcemicos y composiciones con calcio mejoradas para el tratamiento de la hipercalemia.
AU2013290141A AU2013290141A1 (en) 2012-07-11 2013-07-11 Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia
CN201380047054.7A CN104968336A (zh) 2012-07-11 2013-07-11 用于治疗高钙血症患者高钾血症的微孔硅酸锆以及用于治疗高钾血症的改进的含钙组合物
EP13817161.6A EP2872148A4 (en) 2012-07-11 2013-07-11 MICROPOROUS ZIRCONESILICATE FOR THE TREATMENT OF HYPERCALMYME IN HYPERCALCEAN PATIENTS AND IMPROVED CALCIUM-CONTAINING COMPOSITIONS FOR THE TREATMENT OF HYPERKALEMIA
KR1020157003699A KR20150036555A (ko) 2012-07-11 2013-07-11 고칼슘혈증 환자에서 고칼륨혈증의 치료를 위한 미세다공성 지르코늄 실리케이트 및 고칼륨혈증의 치료를 위한 개선된 칼슘-함유 조성물
JP2015521806A JP2015529640A (ja) 2012-07-11 2013-07-11 高カルシウム血症患者における高カリウム血症の治療のための微多孔性ケイ酸ジルコニウム、および高カリウム血症の治療のための改善されたカルシウム含有組成物
CA2878832A CA2878832A1 (en) 2012-07-11 2013-07-11 Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia
IL236655A IL236655A0 (en) 2012-07-11 2015-01-11 Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved preparations containing calcium for the treatment of hyperkalemia
PH12015500071A PH12015500071A1 (en) 2012-07-11 2015-01-12 Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261670415P 2012-07-11 2012-07-11
US61/670,415 2012-07-11
US201361800291P 2013-03-15 2013-03-15
US61/800,291 2013-03-15

Publications (2)

Publication Number Publication Date
WO2014011876A2 true WO2014011876A2 (en) 2014-01-16
WO2014011876A3 WO2014011876A3 (en) 2015-07-16

Family

ID=49916686

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/050071 WO2014011876A2 (en) 2012-07-11 2013-07-11 Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia

Country Status (16)

Country Link
US (1) US9707255B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2872148A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2015529640A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20150036555A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104968336A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013290141A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112015000636A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2878832A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2015000078A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO7200258A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (2) HK1209029A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL236655A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2015KN00201A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2015000381A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12015500071A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014011876A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2981272A4 (en) * 2013-04-05 2016-12-07 Zs Pharma Inc MICROPOROUS ZIRCONIUM MILICATE AND DIURETICS FOR THE REDUCTION OF CALIUM AND THE TREATMENT OF CHRONIC KIDNEY AND / OR CHRONIC HERBAL DISEASES
US9707255B2 (en) 2012-07-11 2017-07-18 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012109590A2 (en) 2011-02-11 2012-08-16 Zs Pharma, Inc Microporous zirconium silicate for the treatment of hyperkalemia
US20160038538A1 (en) * 2013-11-08 2016-02-11 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
KR102332954B1 (ko) * 2013-11-08 2021-11-29 제트에스 파마, 인코포레이티드 고칼륨혈증의 치료를 위한 미세다공성 규산지르코늄
US9592253B1 (en) * 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
US11577014B2 (en) 2019-07-09 2023-02-14 Uop Llc Process for removing strontium ions from bodily fluids using metallate ion exchange compositions
US11964266B2 (en) 2019-07-09 2024-04-23 Uop Llc Process for removing cobalt, lead, cadmium and chromium ions from bodily fluids using metallate ion exchange compositions
US11484875B2 (en) 2019-07-09 2022-11-01 Uop Llc Process for removing mercury ions from bodily fluids using titanium metallate ion exchange compositions
TWI732489B (zh) * 2020-03-17 2021-07-01 國防醫學院 應用心電圖快速偵測鉀離子異常之方法及其系統
US12036528B2 (en) 2020-09-30 2024-07-16 Uop Llc Process for removing lead ions from boldily fluids using metallate ion exchange compositions
CN119643609A (zh) * 2025-02-17 2025-03-18 北京华睿鼎信科技有限公司 一种晶相杂质的分析方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3329480A (en) 1963-10-18 1967-07-04 Union Oil Co Crystalline zircono-silicate zeolites
US3947279A (en) 1971-12-23 1976-03-30 Owens-Illinois, Inc. Thermally crystallizable glasses possessing precision controlled crystallization and flow properties and process of producing same
US3959445A (en) * 1973-04-30 1976-05-25 E. I. Du Pont De Nemours And Company Highly absorbent, low bulk density sodium silicate
US4581141A (en) * 1978-02-27 1986-04-08 Purdue Research Foundation Dialysis material and method for removing uremic substances
FR2444005A1 (fr) 1978-12-15 1980-07-11 Ugine Kuhlmann Procede industriel de fabrication en semi-continu de zeolithe a
LU84743A1 (fr) * 1983-04-11 1984-11-28 Sipac Procede de fabrication de zeolite a et produits obtenus
US4943545A (en) * 1987-06-08 1990-07-24 Mobil Oil Corporation Activation of zeolites
US5032556A (en) 1989-02-21 1991-07-16 Tosoh Corporation Preparation method for zircon powder
US5015453A (en) 1989-04-28 1991-05-14 W. R. Grace & Co.-Conn. Crystalline group IVA metal-containing molecular sieve compositions
JP3265344B2 (ja) 1990-03-16 2002-03-11 東ソー株式会社 ジルコン粉末の合成法
US5338527A (en) 1992-08-20 1994-08-16 Uop Zirconium silicate composition, method of preparation and uses thereof
US5624652A (en) 1992-10-28 1997-04-29 Crosfield Limited Silicas
US5518707A (en) 1994-10-24 1996-05-21 Uop Metallo germanates
GB9601398D0 (en) 1996-01-24 1996-03-27 Piper Edwina M Composition
IT1283284B1 (it) 1996-03-21 1998-04-16 Eniricerche Spa Zeolite ers-10 e procedimento per la sua preparazione
FR2750893B1 (fr) * 1996-07-12 1998-10-30 Elf Aquitaine Procede de synthese de zeolithe avec agitation homogene du milieu, dispositif et application
CA2214495C (en) 1996-09-25 2002-02-05 Daniel L. Woodard Hydrated zirconium silicate composition for purification of nucleic acids
US5891417A (en) * 1997-04-08 1999-04-06 Uop Llc Zirconium silicate and zirconium germanate molecular sieves and process using the same
US5888472A (en) * 1997-04-08 1999-03-30 Uop Llc Zirconium silicate molecular sieves and process using the same
EP0982785A4 (en) * 1997-05-12 2001-04-18 Japan Represented By Director SEPARATOR FOR ACCUMULATOR AND ALKALI ELECTRIC ACCUMULATOR USING THE SAME
JPH11292769A (ja) * 1998-04-10 1999-10-26 Toyo Seiyaku Kasei Kk 高カリウム血症改善剤組成物
US6007790A (en) 1998-08-13 1999-12-28 Uop Llc Family of microporous indium silicate compositions
US5989518A (en) * 1998-12-29 1999-11-23 Uop Llc Process for synthesizing and controlling the particle size and particle size distribution of a molecular sieve
EP1038580B1 (en) * 1999-03-26 2005-05-25 Uop Llc Ammonium ion adsorption process using zirconium silicate and zirconium germanate molecular sieves
US6099737A (en) 1999-03-29 2000-08-08 Uop Llc Process for removing toxins from blood using zirconium metallate or titanium metallate compositions
US6332985B1 (en) * 1999-03-29 2001-12-25 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
US7041274B2 (en) 1999-10-22 2006-05-09 Intevep, S.A. Aluminosilicate compositions, preparation and use
US6379641B1 (en) 2000-05-01 2002-04-30 Uop Llc Microporous rare earth silicates and method of producing same
US6596254B1 (en) 2000-06-12 2003-07-22 Sandia Corporation Niobate-based octahedral molecular sieves
WO2002062356A2 (en) 2001-02-06 2002-08-15 Ash Medical Systems, Inc. Monovalent-selective cation exchangers as oral sorbent therapy
US6579460B1 (en) 2001-03-13 2003-06-17 Uop Llc Process and composition for removing toxins from bodily fluids
US6814871B1 (en) * 2001-07-13 2004-11-09 Uop Llc Process for removing pollutants from aqueous streams
JP2004149525A (ja) * 2002-10-09 2004-05-27 Sekisui Chem Co Ltd カリウムイオン吸着剤及びその製造方法、並びに高カリウム血症治療剤
US6689335B1 (en) 2002-12-19 2004-02-10 Eastman Kodak Company Silver ion sequester and release agent
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
KR100804360B1 (ko) 2003-12-15 2008-02-15 아사히 가세이 케미칼즈 가부시키가이샤 다공성 성형체 및 그의 제조 방법
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7776319B2 (en) * 2004-03-30 2010-08-17 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US7566432B2 (en) 2004-12-28 2009-07-28 Renal Solutions, Inc. Method of synthesizing zirconium phosphate particles
US7967984B2 (en) 2005-06-14 2011-06-28 Asahi Kasei Chemicals Corporation Apparatus for water treatment and method of treating water
CN101321519A (zh) * 2005-09-30 2008-12-10 伊立普萨公司 制备含有交联壳的核-壳型复合物的方法及其得到的核-壳型复合物
CA2624170C (en) 2005-09-30 2014-02-25 Ilypsa, Inc. Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
US8367112B2 (en) 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2007127390A2 (en) 2006-04-28 2007-11-08 Biolife, L.L.C. Materials and methods for wound treatment
US20080292695A1 (en) 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
EP2079660B1 (en) 2007-01-03 2017-01-11 Insilico Co., Ltd. Coordination polymer crystal with porous metal-organic frameworks and preperation method thereof
ES2304890B1 (es) 2007-04-03 2009-10-30 Universidad De Zaragoza Procedimiento de obtencion de esferas de titanosilicato.
DE202009018722U1 (de) 2008-02-26 2012-11-21 Corning Inc. Läutermittel für Silikatgläser
WO2010022381A1 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US8865121B2 (en) 2009-06-18 2014-10-21 Basf Se Organotemplate-free synthetic process for the production of a zeolitic material
US20120070468A1 (en) 2010-09-16 2012-03-22 Uop Llc Removal of toxins from gastrointestinal fluids
WO2012109590A2 (en) 2011-02-11 2012-08-16 Zs Pharma, Inc Microporous zirconium silicate for the treatment of hyperkalemia
JP5982469B2 (ja) 2011-04-08 2016-08-31 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ アシル化触媒の製造方法
US10092688B2 (en) 2011-05-13 2018-10-09 Laura Jean Robinson Medicament kit and method of use
US9527751B2 (en) 2011-11-11 2016-12-27 Basf Se Organotemplate-free synthetic process for the production of a zeolitic material of the CHA-type structure
JP2015510484A (ja) 2012-02-06 2015-04-09 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 有機鋳型を用いない合成からの鉄及び銅含有ゼオライトベータ、及びそのＮＯｘの選択的触媒還元における使用方法
US9475041B2 (en) 2012-04-24 2016-10-25 Basf Se Zeolitic materials and methods for their preparation using alkenyltrialkylammonium compounds
IN2015KN00201A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-07-11 2015-06-12 Zs Pharma Inc
WO2014066407A1 (en) 2012-10-22 2014-05-01 ZS Pharma, Inc. Microporous zirconium silicate for treating hyperkalemia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2872148A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9707255B2 (en) 2012-07-11 2017-07-18 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia
EP2981272A4 (en) * 2013-04-05 2016-12-07 Zs Pharma Inc MICROPOROUS ZIRCONIUM MILICATE AND DIURETICS FOR THE REDUCTION OF CALIUM AND THE TREATMENT OF CHRONIC KIDNEY AND / OR CHRONIC HERBAL DISEASES
US10695366B2 (en) 2013-04-05 2020-06-30 ZS Pharma, Inc. Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
EP2981272B1 (en) 2013-04-05 2023-03-01 ZS Pharma, Inc Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease

Also Published As

Publication number Publication date
CO7200258A2 (es) 2015-02-27
AU2013290141A1 (en) 2015-02-05
JP2015529640A (ja) 2015-10-08
MX2015000381A (es) 2015-11-23
KR20150036555A (ko) 2015-04-07
US9707255B2 (en) 2017-07-18
WO2014011876A3 (en) 2015-07-16
EP2872148A2 (en) 2015-05-20
CA2878832A1 (en) 2014-01-16
HK1209029A1 (en) 2016-03-24
CL2015000078A1 (es) 2015-06-05
US20140105971A1 (en) 2014-04-17
CN104968336A (zh) 2015-10-07
HK1215861A1 (zh) 2016-09-23
IN2015KN00201A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-06-12
PH12015500071A1 (en) 2015-03-16
EP2872148A4 (en) 2016-06-15
IL236655A0 (en) 2015-02-26
BR112015000636A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
AU2016204124B2 (en) Microporous zirconium silicate for the treatment of hyperkalemia
AU2013334776B2 (en) Microporous zirconium silicate for treating hyperkalemia
US9707255B2 (en) Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia
US10695365B2 (en) Microporous zirconium silicate for the treatment of hyperkalemia
EP3079706A1 (en) Zirconium silicate for treating hyperkalemia without co-administering lithium

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13817161

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2878832

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/000381

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 236655

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2015000078

Country of ref document: CL

Ref document number: 12015500071

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2015521806

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013290141

Country of ref document: AU

Date of ref document: 20130711

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013817161

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 15025901

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 20157003699

Country of ref document: KR

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015000636

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015000636

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150112